Ligand Pharmaceuticals, Inc. (LGND) Tops Q1 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Roth Affirms Ligand Pharma (LGND) at 'Buy'; Captisol, Promacta Lead Strong Q1 Results
May 7, 2014 11:49 AM EDTRoth Capital is commenting on Ligand Pharmaceuticals, Inc. (NASDAQ: LGND) following the company's Q1 report. Roth has Ligand at Buy with a price target of $92.
Earlier, Ligand reported Q1 EPS of $0.35, $0.10 better than the analyst estimate of $0.25. Revenue for the quarter came in at $16 million versus the consensus estimate of $13.63... More
